Association between clot composition and stroke origin in mechanical thrombectomy patients: analysis of the Stroke Thromboembolism Registry of Imaging and Pathology.
stroke
thrombectomy
Journal
Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
05
12
2020
revised:
06
02
2021
accepted:
21
02
2021
pubmed:
17
3
2021
medline:
21
7
2021
entrez:
16
3
2021
Statut:
ppublish
Résumé
We retrospectively evaluated the composition of retrieved clots from ischemic stroke patients to study the association between histological composition and stroke etiology METHODS: Consecutive patients enrolled in the Stroke Thromboembolism Registry of Imaging and Pathology (STRIP) were included in this study. All patients underwent mechanical thrombectomy and retrieved clots were sent to a central core lab for processing. Histological analysis was performed using martius scarlet blue (MSB) staining, and quantification for red blood cells (RBCs), white blood cells (WBCs), fibrin and platelets was performed using Orbit Image Software. A Wilcoxon test was used for continuous variables and χ 1350 patients were included in this study. The overall rate of Thrombolysis In Cerebral Infarction (TICI) 2c/3 was 68%. 501 patients received tissue plasminogen activator (tPA) (37%). 267 patients (20%) had a large artery atherosclerosis (LAA) source, 662 (49%) a cardioembolic (CE) source, 301 (22%) were cryptogenic, and the remainder had other identifiable sources including hypercoagulable state or dissection. LAA thrombi had a higher mean RBC density (46±23% vs 42±22%, p=0.01) and a lower platelet density (24±18% vs 27±18%, p=0.03) than CE thrombi. Clots from dissection patients had the highest mean RBC density (50±24%) while clots from patients with a hypercoagulable state had the lowest mean RBC density (26±21%). Our study found statistically significant but clinically insignificant differences between clots of CE and LAA etiologies. Future studies should emphasize molecular, proteomic and immunohistochemical characteristics to determine links between clot composition and etiology.
Sections du résumé
BACKGROUND
BACKGROUND
We retrospectively evaluated the composition of retrieved clots from ischemic stroke patients to study the association between histological composition and stroke etiology METHODS: Consecutive patients enrolled in the Stroke Thromboembolism Registry of Imaging and Pathology (STRIP) were included in this study. All patients underwent mechanical thrombectomy and retrieved clots were sent to a central core lab for processing. Histological analysis was performed using martius scarlet blue (MSB) staining, and quantification for red blood cells (RBCs), white blood cells (WBCs), fibrin and platelets was performed using Orbit Image Software. A Wilcoxon test was used for continuous variables and χ
RESULTS
RESULTS
1350 patients were included in this study. The overall rate of Thrombolysis In Cerebral Infarction (TICI) 2c/3 was 68%. 501 patients received tissue plasminogen activator (tPA) (37%). 267 patients (20%) had a large artery atherosclerosis (LAA) source, 662 (49%) a cardioembolic (CE) source, 301 (22%) were cryptogenic, and the remainder had other identifiable sources including hypercoagulable state or dissection. LAA thrombi had a higher mean RBC density (46±23% vs 42±22%, p=0.01) and a lower platelet density (24±18% vs 27±18%, p=0.03) than CE thrombi. Clots from dissection patients had the highest mean RBC density (50±24%) while clots from patients with a hypercoagulable state had the lowest mean RBC density (26±21%).
CONCLUSIONS
CONCLUSIONS
Our study found statistically significant but clinically insignificant differences between clots of CE and LAA etiologies. Future studies should emphasize molecular, proteomic and immunohistochemical characteristics to determine links between clot composition and etiology.
Identifiants
pubmed: 33722963
pii: neurintsurg-2020-017167
doi: 10.1136/neurintsurg-2020-017167
pmc: PMC9069417
mid: NIHMS1789900
doi:
Substances chimiques
Fibrin
9001-31-4
PLAT protein, human
EC 3.4.21.68
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
594-598Subventions
Organisme : NINDS NIH HHS
ID : R01 NS105853
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Stroke. 2017 Aug;48(8):2206-2210
pubmed: 28626055
J Neurointerv Surg. 2017 Jun;9(6):529-534
pubmed: 27166383
Int J Mol Sci. 2018 Feb 07;19(2):
pubmed: 29414888
Stroke. 2018 Nov;49(11):2674-2682
pubmed: 30355200
Stroke. 2016 Jul;47(7):1864-71
pubmed: 27197854
J Neurointerv Surg. 2021 Oct;13(10):906-911
pubmed: 33361274
Med Sci Monit. 2018 Jun 11;24:3929-3945
pubmed: 29887594
Int J Stroke. 2017 Aug;12(6):606-614
pubmed: 28534706
J Neurointerv Surg. 2021 Dec;13(12):1111-1116
pubmed: 33298510
Neuroimaging Clin N Am. 2018 Nov;28(4):611-623
pubmed: 30322597
J Neurointerv Surg. 2020 Jan;12(1):38-42
pubmed: 31239329
Stroke. 2019 Jul;50(7):1907-1910
pubmed: 31138084
AJNR Am J Neuroradiol. 2015 Sep;36(9):1756-62
pubmed: 26159515
Stat Appl Genet Mol Biol. 2007;6:Article25
pubmed: 17910531
J Neurosurg Sci. 2019 Jun;63(3):292-300
pubmed: 30514073
PLoS One. 2019 Dec 5;14(12):e0225841
pubmed: 31805096
Neurology. 2019 Oct 29;93(18):e1686-e1698
pubmed: 31541014